What is Verve Therapeutics Debt-to-Equity?
Verve Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $10.44 Mil. Verve Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $59.54 Mil. Verve Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $493.40 Mil.
Verve Therapeutics's debt to equity for the quarter that ended in Dec. 2024 was 0.14.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Verve Therapeutics's Debt-to-Equity or its related term are showing as below:
VERV'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.13 Max: 0.15
Current: 0.14
During the past 6 years, the highest Debt-to-Equity Ratio of Verve Therapeutics was 0.15. The lowest was 0.01. And the median was 0.13.
Verve Therapeutics Debt-to-Equity Historical Data
The historical data trend for Verve Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verve Therapeutics Debt-to-Equity Chart
|
Verve Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
Dec24 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
- |
0.01 |
0.15 |
0.13 |
0.14 |
|
Verve Therapeutics Quarterly Data
|
|
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
Jun24 |
Sep24 |
Dec24 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.13 |
0.13 |
0.13 |
0.14 |
0.14 |
Competitive Comparison of Verve Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Verve Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verve Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verve Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Verve Therapeutics's Debt-to-Equity falls into.
Verve Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Verve Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Verve Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verve Therapeutics Business Description
Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Executives
| Joan Nickerson |
officer: Chief Administrative Officer |
C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215 |
| Sekar Kathiresan |
director, 10 percent owner, officer: Chief Executive Officer |
500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Andrew D. Ashe |
officer: See Remarks |
C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Allison Dorval |
officer: Chief Financial Officer |
C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
| Krishna Yeshwant |
director, 10 percent owner |
C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
| Fred T. Fiedorek |
officer: Chief Medical Officer |
55 BALDWIN LANE, PRINCETON NJ 08540 |
| Andrew Bellinger |
officer: Chief Scientific Officer |
500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Gv 2017 Gp, L.l.c. |
10 percent owner |
1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
| Alphabet Inc. |
other: Member of 10% Group |
1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
| Lonnel Coats |
director |
8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
| Fmr Llc |
10 percent owner, other: See Remark 1 |
245 SUMMER STREET, BOSTON MA 02210 |
| Alexander Cumbo |
director |
215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
| Burt A Adelman |
director, 10 percent owner |
DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Cormorant Asset Management, Lp |
10 percent owner |
200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
| Logos Global Management Lp |
10 percent owner |
1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129 |
Verve Therapeutics Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VERV has been successfully added to your